FDA rejects China-developed cancer drug Ivonescimab, setback for Beijing biotech
Published 3 d ago2 sourcesEvidence: Reported
The FDA declined approval for a Chinese cancer drug, citing insufficient evidence of improved survival. The drug is already in clinical use in China, highlighting divergent regulatory standards. This may affect the developer's US market prospects and cross-border pharma dynamics.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 3 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 20 h ago1 sourceEvidence: Reported
Published 3 d ago13 sourcesEvidence: Unknown
Published 2 d ago16 sourcesEvidence: Reported
Published 13 h ago6 sourcesEvidence: Reported